Cited by 185Inhalation and Respiratory Drug DeliveryTuberculosis Research and EpidemiologyAdvanced Drug Delivery Systems

The DOI matches its Crossref record; 117 of the 121 references it cites were found in a registry or an index.

Pulmonary drug delivery systems for tuberculosis treatment

Pham, Dinh-Duy, Fattal, Elias, Tsapis, Nicolas·2015·International Journal of Pharmaceutics

DOI 10.1016/j.ijpharm.2014.12.009

Open this paper in CoChat — free account

Abstract

Tuberculosis (TB) remains a major global health problem as it is the second leading cause of death from an infectious disease worldwide, after the human immunodeficiency virus (HIV). Conventional treatments fail either because of poor patient compliance to the drug regimen or due to the emergence of multidrug-resistant tuberculosis. The aim of this review is to give an update on the information available on tuberculosis, its pathogenesis and current antitubercular chemotherapies. Direct lung delivery of anti-TB drugs using pulmonary delivery systems is then reviewed since it appears as an interesting strategy to improve first and second line drugs. A particular focus is place on research performed on inhalable dry powder formulations of antitubercular drugs to target alveolar macrophages where the bacteria develop. Numerous studies show that anti-TB drugs can be incorporated into liposomes, microparticles or nanoparticles which can be delivered as dry powders to the deep lungs for instantaneous, targeted and/or controlled release. Treatments of infected animals show a significant reduction of the number of viable bacteria as well as a decrease in tissue damage. These new formulations appear as interesting alternatives to deliver directly drugs to the lungs and favor efficient TB treatment.

Integrity signals

Registry

Crossref · 10.1016/j.ijpharm.2014.12.009

Cites

117 of 117 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Global tuberculosis report (2014)
Gabbasova, L. A., & Who, E. R. E. (2014) · Cited by 12,702
Aerosol Technology Properties, Behavior, and Measurement of Airborne Particles
Laucks, M. L. (2000) · Journal of Aerosol Science · doi:10.1016/s0021-8502(99)00571-6 · Cited by 3,426
American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis
Blumberg, H. M., Burman, W. J., Chaisson, R. E., Daley, C. L., Etkind, S. C., Friedman, L. N., Fujiwara, P., Grzemska, M., Hopewell, P. C., Iseman, M. D., et al. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.167.4.603 · Cited by 1,936
Diagnostic Standards and Classification of Tuberculosis in Adults and Children: This Official Statement of the American Thoracic Society and the Centers for Disease Control and Prevention was Adopted by the ATS Board of Directors, July 1999. This Statement was endorsed by the Council of the Infectious Disease Society of America, September 1999
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.4.16141 · Cited by 1,524
Large Porous Particles for Pulmonary Drug Delivery
Edwards, D. A., Hanes, J. S., Caponetti, G., Hrkach, J. S., Ben-Jebria, A., Eskew, M. L., Mintzes, J. D., Deaver, D. R., Lotan, N., & Langer, R. (1997) · Science · doi:10.1126/science.276.5320.1868 · Cited by 1,184
Deposition of particles in the human respiratory tract in the size range 0.005–15 μm
Heyder, J., Gebhart, J., Rudolf, G., Schiller-Scotland, C. F., & STAHLHOFEN, W. (1986) · Journal of Aerosol Science · doi:10.1016/0021-8502(86)90035-2 · Cited by 1,034
Global Tuberculosis Control 2011, WHO Report 2011
Behera, D. (2012) · The Indian Journal of Medical Research · Cited by 1,022
Administration of substances to laboratory animals: routes of administration and factors to consider.
Turner, P. V., Brabb, T., Pekow, C. A., & Vasbinder, M. A. (2011) · PubMed Central · Cited by 982
Tuberculosis: Pathogenesis, Protection and Control
(1996) · Nature Medicine · doi:10.1038/nm0296-244b · Cited by 977
Development of Nanoparticles for Antimicrobial Drug Delivery
Zhang, L., Pornpattananangkul, D., Hu, C.-M., & Huang, C.-W. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710790416290 · Cited by 904
Lung biology in health and disease
Horsmanheimo, M., & Fudenberg, H. H. (1977) · Clinical Immunology and Immunopathology · doi:10.1016/0090-1229(77)90040-x · Cited by 798
Treatment of Multidrug-Resistant Tuberculosis
Wood, A. J. J., & Iseman, M. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199309093291108 · Cited by 705
Nanoparticles for drug delivery to the lungs
Sung, J. C., Pulliam, B., & Edwards, D. A. (2007) · Trends in biotechnology · doi:10.1016/j.tibtech.2007.09.005 · Cited by 659
Global Tuberculosis Control: WHO Report 2011
Williams, C. (2012) · Australian and New Zealand Journal of Public Health · doi:10.1111/j.1753-6405.2012.00928.x · Cited by 588
Trojan particles: Large porous carriers of nanoparticles for drug delivery
Tsapis, N., Bennett, D., Jackson, B., Weitz, D. A., & Edwards, D. A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182233999 · Cited by 551
Self-citation
Tuberculosis in Patients with the Acquired Immunodeficiency Syndrome: Clinical Features, Response to Therapy, and Survival
Chaisson, R. E., Schecter, G. F., Theuer, C. P., Rutherford, G. W., Echenberg, D. F., & Hopewell, P. C. (1987) · American Review of Respiratory Disease · doi:10.1164/ajrccm/136.3.570 · Cited by 453
New insights into the function of granulomas in human tuberculosis
Ulrichs, T., & Kaufmann, S. H. E. (2006) · Journal of Pathology · doi:10.1002/path.1906 · Cited by 421
Lippincott's Illustrated Reviews: Pharmacology
Whalen, K., Finkel, R. S., & Panavelil, T. A. (1991) · Cited by 415
Delivery strategies for sustained drug release in the lungs
Loira-Pastoriza, C., Todoroff, J., & Rita Vanbever, A. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.05.017 · Cited by 395
Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis
Pandey, R. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg477 · Cited by 389
Liposomes: A Review of Manufacturing Techniques and Targeting Strategies
Maherani, B., Arab‐Tehrany, E., Mozafari, M. R., Gaïani, C., & Linder, M. (2011) · Current Nanoscience · doi:10.2174/157341311795542453 · Cited by 369
Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis
Pandey, R., & Khuller, G. K. (2005) · Tuberculosis · doi:10.1016/j.tube.2004.11.003 · Cited by 318
Treatment of multidrug-resistant pulmonary tuberculosis with interferon-γ via aerosol
Condos, R., Rom, W. N., & Schluger, N. W. (1997) · The Lancet · doi:10.1016/s0140-6736(96)12273-x · Cited by 317
Formulation and Physical Characterization of Large Porous Particles for Inhalation
Rita Vanbever, A., Mintzes, J. D., Wang, J., Nice, J., Chen, D., Batycky, R., Langer, R., & Edwards, D. A. (1999) · Pharmaceutical Research · doi:10.1023/a:1018910200420 · Cited by 315
Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis
Zahoor, A., Sharma, S., & Khuller, G. K. (2005) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2005.07.012 · Cited by 314
Manual of clinical microbiology
Lennette, E. H. (1982) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/0278-2391(82)90036-2 · Cited by 302
Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance
Bosquillon, C., Lombry, C., Véronique Préat, A., & Rita Vanbever, A. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(00)00362-x · Cited by 296
Tuberculosis in patients with the acquired immunodeficiency syndrome
Richard, R. (1987) · Medical Entomology and Zoology · Cited by 294
Interactions of antigen-loaded polylactide particles with macrophages and their correlation with the immune response
Kanchan, V., & Panda, A. K. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2007.08.015 · Cited by 283
Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages
Vyas, S. P., Kannan, M., Jain, S., Mishra, V. K., & Singh, P. (2003) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2003.08.017 · Cited by 262
Dry powder inhalers for pulmonary drug delivery
Frijlink, H. W., & de Boer, A. H. (2004) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.1.1.67 · Cited by 259
Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis
Sharma, A., Sharma, S., & Khuller, G. K. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh411 · Cited by 251
Formulation and Pharmacokinetics of Self-Assembled Rifampicin Nanoparticle Systems for Pulmonary Delivery
Sung, J. C., Padilla, D. J., Garcia‐Contreras, L., VerBerkmoes, J. L., Durbin, D., Peloquin, C. A., Elbert, K. J., Hickey, A. J., & Edwards, D. A. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9894-2 · Cited by 247
Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases
Andrade, F., Rafael, D., Videira, M., Ferreira, D., Sosnik, A., & Sarmento, B. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.07.020 · Cited by 245
Respirable PLGA Microspheres Containing Rifampicin for the Treatment of Tuberculosis: Manufacture and Characterization
O’Hara, P. J., & Hickey, A. J. (2000) · Pharmaceutical Research · doi:10.1023/a:1007527204887 · Cited by 242
Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis
Pandey, R., Zahoor, A., Sharma, S., & Khuller, G. K. (2003) · Tuberculosis · doi:10.1016/j.tube.2003.07.001 · Cited by 220
Tuberculosis chemotherapy: current drug delivery approaches
du Toit, L. C., Pillay, V., & Danckwerts, M. P. (2006) · Respiratory Research · doi:10.1186/1465-9921-7-118 · Cited by 213
Inhalable Microparticles Containing Drug Combinations to Target Alveolar Macrophages for Treatment of Pulmonary Tuberculosis
Sharma, R., Saxena, D., Dwivedi, A. K., & Misra, A. (2001) · Pharmaceutical Research · doi:10.1023/a:1012296604685 · Cited by 201
Epidemiology of selected mycobacteria that infect humans and other animals
Ashford, D. A., Whitney, E. A. S., Raghunathan, P. L., & Cosivi, O. (2001) · Scientific and Technical Review (World Organisation for Animal Health) · doi:10.20506/rst.20.1.1266 · Cited by 191
Antitubercular inhaled therapy: opportunities, progress and challenges
Pandey, R., & Khuller, G. K. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki027 · Cited by 188
Golden Holocaust: Origins of the Cigarette Catastrophe and the Case for Abolition
Daube, M. (2012) · Australian and New Zealand Journal of Public Health · doi:10.1111/j.1753-6405.2012.00927.x · Cited by 187
One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis
Ohashi, K., Kabasawa, T., Ozeki, T., & Okada, H. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.11.027 · Cited by 178
The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis.
Blomberg, B., Spinaci, S., Fourie, B. P., & Laing, R. O. (2001) · Europe PMC (PubMed Central) · Cited by 176
Inhalable microparticles containing large payload of anti-tuberculosis drugs
Muttil, P., Kaur, J. P., Kumar, K., Yadav, A. B., Sharma, R., & Misra, A. (2007) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2007.06.006 · Cited by 173
Delivery of Biotherapeutics by Inhalation Aerosol
Niven, R. W. (1995) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v12.i2-3.20 · Cited by 164
Immunopathogenesis of Pulmonary Tuberculosis
Dannenberg, A. M. (1993) · Hospital Practice · doi:10.1080/21548331.1993.11442738 · Cited by 164
Respirable PLGA Microspheres Containing Rifampicin for the Treatment of Tuberculosis: Screening in An Infectious Disease Model
Suarez, S., O’Hara, P. J., Kazantseva, M., Newcomer, C. E., Hopfer, R. L., McMurray, D. N., & Hickey, A. J. (2001) · Pharmaceutical Research · doi:10.1023/a:1013094112861 · Cited by 159
Airways delivery of rifampicin microparticles for the treatment of tuberculosis
Suarez, S. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/48.3.431 · Cited by 156
Inhaled Drug Delivery for Tuberculosis Therapy
Muttil, P., Wang, C., & Hickey, A. J. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9957-4 · Cited by 148
Therapeutic Liposomal Dry Powder Inhalation Aerosols for Targeted Lung Delivery
Willis, L., Hayes, D., & Mansour, H. M. (2012) · Lung · doi:10.1007/s00408-011-9360-x · Cited by 148
Efficient intracellular delivery of rifampicin to alveolar macrophages using rifampicin-loaded PLGA microspheres: effects of molecular weight and composition of PLGA on release of rifampicin
Makino, K., Nakajima, T., Shikamura, M., Ito, F., Ando, S., Kochi, C., Inagawa, H., Soma, G., & Terada, H. (2004) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2004.03.018 · Cited by 145
Inhaled Large Porous Particles of Capreomycin for Treatment of Tuberculosis in a Guinea Pig Model
Garcia‐Contreras, L., Fiegel, J., Telko, M. J., Elbert, K. J., Hawi, A. A., Thomas, M., VerBerkmoes, J. L., Germishuizen, W. A., Fourie, P. B., Hickey, A. J., et al. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01164-06 · Cited by 139
New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes
Lienhardt, C., Vernon, A., & Raviglione, M. C. (2010) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e328337580c · Cited by 137
Dry powder platform for pulmonary drug delivery
Daniher, D., & Zhu, J. (2008) · Particuology · doi:10.1016/j.partic.2008.04.004 · Cited by 133
Delivery of rifampicin–PLGA microspheres into alveolar macrophages is promising for treatment of tuberculosis
Hirota, K., Hasegawa, T., Nakajima, T., Inagawa, H., Kohchi, C., Soma, G., Makino, K., & Terada, H. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.11.020 · Cited by 130
Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice
Deol, P., Khuller, G. K., & Joshi, K. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.6.1211 · Cited by 128
Isoniazid Proliposome Powders for Inhalation—Preparation, Characterization and Cell Culture Studies
Rojanarat, W., Changsan, N., Tawithong, E., Pinsuwan, S., Chan, H., & Srichana, T. (2011) · International Journal of Molecular Sciences · doi:10.3390/ijms12074414 · Cited by 120
New drugs for the treatment of tuberculosis: hope and reality [State of the Art Series. New tools. Number 2 in the series]
Grosset, J. H. E., Singer, T. G., & Bishai, W. R. (2012) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.12.0277 · Cited by 119
Respirable nanocarriers as a promising strategy for antitubercular drug delivery
Mehanna, M. M., Mohyeldin, S. M., & Elgindy, N. A. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.038 · Cited by 119
Polymer Based Drug Delivery Systems for Mycobacterial Infections
Pandey, R., & Khuller, G. K. (2004) · Current Drug Delivery · doi:10.2174/1567201043334669 · Cited by 116
Use of Microsphere Technology for Targeted Delivery of Rifampin to Mycobacterium tuberculosis -Infected Macrophages
Barrow, E. L. W., Winchester, G. A., Staas, J. K., Quenelle, D. C., & Barrow, W. W. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.10.2682 · Cited by 113
Physicochemical Characterization and Stability of Rifampicin Liposome Dry Powder Formulations for Inhalation
Changsan, N., Chan, H., Separovic, F., & Srichana, T. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21441 · Cited by 108
Pulmonary distribution and clearance of two beclomethasone liposome formulations in healthy volunteers
Saari, M., Vidgren, M. T., Koskinen, M. O., Turjanmaa, V., & Nieminen, M. M. (1999) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(98)00398-6 · Cited by 105
Recent advances in liposomal dry powder formulations: preparation and evaluation
Misra, A. R., Jinturkar, K., Patel, D. H., Lalani, J., & Chougule, M. B. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240802652309 · Cited by 103
No lung toxicity after repeated aerosol or intravenous delivery of plasmid-cationic liposome complexes
Canonico, A. E., Plitman, J. D., Conary, J. T., Meyrick, B. O., & Brigham, K. L. (1994) · Journal of Applied Physiology · doi:10.1152/jappl.1994.77.1.415 · Cited by 103
A novel dry powder inhalable formulation incorporating three first-line anti-tubercular antibiotics
Chan, J. G. Y., Chan, H., Prestidge, C. A., Denman, J. A., Young, P. M., & Traini, D. (2012) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2012.08.007 · Cited by 100
Intracellular Time Course, Pharmacokinetics, and Biodistribution of Isoniazid and Rifabutin following Pulmonary Delivery of Inhalable Microparticles to Mice
Verma, R. K., Kaur, J. P., Kumar, K., Yadav, A. B., & Misra, A. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00153-08 · Cited by 96
Preparation and in Vivo Evaluation of a Dry Powder for Inhalation of Capreomycin
Fiegel, J., Garcia‐Contreras, L., Thomas, M., VerBerkmoes, J. L., Elbert, K. J., Hickey, A. J., & Edwards, D. A. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9381-6 · Cited by 95
Lectin-functionalized liposomes for pulmonary drug delivery: effect of nebulization on stability and bioadhesion
Abu‐Dahab, R., Schäfer, U. F., & Lehr, C. (2001) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(01)00147-6 · Cited by 95
Uptake of inhalable microparticles affects defence responses of macrophages infected with Mycobacterium tuberculosis H37Ra
Sharma, R., Muttil, P., Yadav, A. B., Rath, S. K., Bajpai, V. K., Mani, U., & Misra, A. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl533 · Cited by 94
Acute Effects of Liposome Aerosol Inhalation on Pulmonary Function in Healthy Human Volunteers
Thomas, D. A., Myers, M. A., Wichert, B. M., Schreier, H., & Gonzalez‐Rothi, R. J. (1991) · CHEST Journal · doi:10.1378/chest.99.5.1268 · Cited by 83
Slow Release Formulations of Inhaled Rifampin
Coowanitwong, I., Arya, V., Kulvanich, P., & Hochhaus, G. (2008) · The AAPS Journal · doi:10.1208/s12248-008-9044-5 · Cited by 79
Inhaled pyrazinamide proliposome for targeting alveolar macrophages
Rojanarat, W., Nakpheng, T., Thawithong, E., Yanyium, N., & Srichana, T. (2012) · Drug Delivery · doi:10.3109/10717544.2012.721144 · Cited by 79
Six-month Therapy with Aerosolized Interferon-γ for Refractory Multidrug-Resistant Pulmonary Tuberculosis
Koh, W., Kwon, O. J., Suh, G. Y., Chung, M. P., Kim, H., Lee, N. Y., Kim, T., & Lee, K. S. (2004) · Journal of Korean Medical Science · doi:10.3346/jkms.2004.19.2.167 · Cited by 79
Incorporation of Antibiotics in Liposomes Designed for Tuberculosis Therapy by Inhalation
Justo, O. R., & Moraes, Â. M. (2003) · Drug Delivery · doi:10.1080/713840401 · Cited by 77
Dry Powder PA-824 Aerosols for Treatment of Tuberculosis in Guinea Pigs
Garcia‐Contreras, L., Sung, J. C., Muttil, P., Padilla, D., Telko, M., VerBerkmoes, J. L., Elbert, K. J., Hickey, A. J., & Edwards, D. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01471-09 · Cited by 76
In vitro evaluation of inhalable isoniazid‐loaded surfactant liposomes as an adjunct therapy in pulmonary tuberculosis
Chimote, G., & Banerjee, R. (2010) · Journal of Biomedical Materials Research Part B Applied Biomaterials · doi:10.1002/jbm.b.31608 · Cited by 75
An inducible autocrine cascade regulates rat hepatocyte proliferation and apoptosis responses to tumor necrosis factor‐α†‡
Cosgrove, B. D., Cheng, C., Pritchard, J. R., Stolz, D. B., Lauffenburger, D. A., & Griffith, L. G. (2008) · Hepatology · doi:10.1002/hep.22335 · Cited by 75
Enhanced Anti-Inflammation of Inhaled Dexamethasone Palmitate Using Mannosylated Liposomes in an Endotoxin-Induced Lung Inflammation Model
Wijagkanalan, W., Higuchi, Y., Kawakami, S., Teshima, M., Sasaki, H., & Hashida, M. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.050153 · Cited by 74
Direct lung delivery of para-aminosalicylic acid by aerosol particles
Tsapis, N., Bennett, D., O'Driscoll, K. M., Shea, K., Lipp, M., Fu, K., Clarke, R. W., Deaver, D. R., Yamins, D. L. K., Wright, J. E., et al. (2003) · Tuberculosis · doi:10.1016/j.tube.2003.08.016 · Cited by 72
Self-citation
Dry Powder Nitroimidazopyran Antibiotic PA-824 Aerosol for Inhalation
Sung, J. C., Garcia‐Contreras, L., VerBerkmoes, J. L., Peloquin, C. A., Elbert, K. J., Hickey, A. J., & Edwards, D. A. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01389-08 · Cited by 72
Understanding Tuberculosis - New Approaches to Fighting Against Drug Resistance
Cardona, P.-J. (2012) · InTech eBooks · doi:10.5772/2477 · Cited by 71
Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug
Sethuraman, V. V., & Hickey, A. J. (2002) · AAPS PharmSciTech · doi:10.1208/pt030428 · Cited by 68
Levofloxacin-Proliposomes: Opportunities for Use in Lung Tuberculosis
Rojanarat, W., Nakpheng, T., Thawithong, E., Yanyium, N., & Srichana, T. (2012) · Pharmaceutics · doi:10.3390/pharmaceutics4030385 · Cited by 67
Effects of Gender, AIDS, and Acetylator Status on Intrapulmonary Concentrations of Isoniazid
Conte, J. E., Golden, J. A., McQuitty, M., Kipps, J., Duncan, S., McKenna, E., & Zurlinden, E. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.8.2358-2364.2002 · Cited by 65
Did we reach the 2005 targets for tuberculosis control?
Dye, C. (2007) · Bulletin of the World Health Organization · doi:10.2471/blt.06.037580 · Cited by 64
Adjunctive Salvage Therapy with Inhaled Aminoglycosides for Patients with Persistent Smear-Positive Pulmonary Tuberculosis
Sacks, L. V., Pendle, S., Orlovic, D., Andre, M., Popara, M., Moore, G. A., Thonell, L., & Hurwitz, S. (2001) · Clinical Infectious Diseases · doi:10.1086/317524 · Cited by 64
Selective delivery of rifampicin incorporated into poly(dl-lactic-co-glycolic) acid microspheres after phagocytotic uptake by alveolar macrophages, and the killing effect against intracellular Mycobacterium bovis Calmette–Guérin
Yoshida, A., Matumoto, M., Hshizume, H., Oba, Y., Tomishige, T., Inagawa, H., Kohchi, C., Hino, M., Ito, F., Tomoda, K., et al. (2006) · Microbes and Infection · doi:10.1016/j.micinf.2006.06.004 · Cited by 63
Nebulization of liposome encapsulated antitubercular drugs in guinea pigs
Pandey, R., Sharma, S., & Khuller, G. K. (2004) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2004.04.004 · Cited by 63
Osmotically regulated asymmetric capsular systems for simultaneous sustained delivery of anti-tubercular drugs
Prabakaran, D. S., Singh, P., Jaganathan, K. S., & Vyas, S. P. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2003.11.013 · Cited by 62
Formation of Inhalable Rifampicin–Poly(l-lactide) Microparticles by Supercritical Anti-solvent Process
Patomchaiviwat, V., Paeratakul, O., & Kulvanich, P. (2008) · AAPS PharmSciTech · doi:10.1208/s12249-008-9152-7 · Cited by 62
Microparticle-based lung delivery of INH decreases INH metabolism and targets alveolar macrophages
Zhou, H., Zhang, Y., Biggs, D. L., Manning, M. C., Randolph, T. W., Christians, U., Hybertson, B. M., & Ng, K. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.06.009 · Cited by 61
Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels
Agrawal, S., Singh, I., Kaur, K. J., Bhade, S. R., Kaul, C. L., & Panchagnula, R. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2004.02.019 · Cited by 61
Liposomal amikacin dry powder inhaler: Effect of fines on in vitro performance
Shah, S. P., & Misra, A. R. (2004) · AAPS PharmSciTech · doi:10.1208/pt050465 · Cited by 58
Iron enhances the antituberculous activity of pyrazinamide
Somoskövi, Á. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh042 · Cited by 58
Sustained release of insulin from insoluble inhaled particles
Rita Vanbever, A., Jebria, A. B., Mintzes, J. D., Langer, R., & Edwards, D. A. (1999) · Drug Development Research · doi:10.1002/(sici)1098-2299(199912)48:4 · Cited by 56
Pulmonary Delivery of Inhalable Nanoparticles: Dry Powder Inhalers
Alhallak, K., Sarfraz, M., Azarmi, S., Roa, W., Finlay, W. H., & Löbenberg, R. (2011) · Therapeutic Delivery · doi:10.4155/tde.11.100 · Cited by 55
Liposomes for Drug Delivery to the Respiratory Tract
Taylor, K. M. G., & Fan, S. J. (1993) · Drug Development and Industrial Pharmacy · doi:10.3109/03639049309038764 · Cited by 52
Formulation of pyrazinamide-loaded large porous particles for the pulmonary route: Avoiding crystal growth using excipients
Pham, D.-D., Fattal, E., Ghermani, N., Guiblin, N., & Tsapis, N. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.04.016 · Cited by 51
Self-citation
Capreomycin supergenerics for pulmonary tuberculosis treatment: Preparation, in vitro, and in vivo characterization
Schoubben, A., Blasi, P., Marenzoni, M. L., Barberini, L., Giovagnoli, S., Cirotto, C., & Ricci, M. (2012) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2012.11.005 · Cited by 48
Monocyte Recruitment in Tuberculosis and Sarcoidosis
Schmitt, E., Meuret, G. H., & Stix, L. (1977) · British Journal of Haematology · doi:10.1111/j.1365-2141.1977.tb00557.x · Cited by 47
Pharmaceutical aerosols for the treatment and prevention of Tuberculosis
Hanif, S. N. M., & Garcia‐Contreras, L. (2012) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2012.00118 · Cited by 45
Effects of lung surfactants on rifampicin release rate from monodisperse rifampicin-loaded PLGA microspheres
Tomoda, K., & Makino, K. (2006) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2006.11.030 · Cited by 44
Monitoring safety of liposomes containing rifampicin on respiratory cell lines andin vitroefficacy againstMycobacterium bovisin alveolar macrophages
Changsan, N., Nilkaeo, A., Pungrassami, P., & Srichana, T. (2009) · Journal of drug targeting · doi:10.3109/10611860903079462 · Cited by 42
Dry powder cationic lipopolymeric nanomicelle inhalation for targeted delivery of antitubercular drug to alveolar macrophage
Kumar, G. S. V., Vadakkan, M. V., Annapoorna, Sivakumar, M., & Mundayoor, S. (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s47456 · Cited by 42
Inhalable microparticles containing isoniazid and rifabutin target macrophages and 'stimulate the phagocyte' to achieve high efficacy.
Yadav, A. B., Sharma, R., Muttil, P., Singh, A. K., Verma, R. K., Mohan, M., Patel, S. K. S., & Misra, A. (2009) · PubMed · Cited by 36
In vitro and in vivo evaluation of the effects of PLA microparticle crystallinity on cellular response
Biggs, D. L., Lengsfeld, C., Hybertson, B. M., Ng, K., Manning, M. C., & Randolph, T. W. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(03)00325-0 · Cited by 34
Old and New TB Drugs: Mechanisms of Action and Resistance
Anastasia, S., & Petros, C. (2012) · InTech eBooks · doi:10.5772/30992 · Cited by 32
Overview of Clinical Tuberculosis
Hopewell, P. C., & Jasmer, R. M. (2004) · doi:10.1128/9781555817657.ch2 · Cited by 31
Antituberculosis therapy for 2012 and beyond
Lauzardo, M., & Peloquin, C. A. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.657176 · Cited by 24
Inhalation Drug Delivery
(2013) · Wiley eBooks · doi:10.1002/9781118397145 · Cited by 23
[Effectiveness of liposomal antibacterial drugs in the inhalation therapy of experimental tuberculosis].
Kurunov, I. N., Ursov, I. G., Va, K., Petrenko, T. I., Nn, I., Владимирович, С. А., & Pa, F. (1995) · PubMed · Cited by 21
Formulation and evalution of montelukast sodium - chitosan based spray dried microspheres for pulmonary drug delivery
Panchal, R., Patel, H., Patel, V. A., Joshi, P. U., & Parikh, A. R. (2012) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/0975-7406.94160 · Cited by 20
INFLUENCE OF FORMULATION COMPONENTS ON AEROSOLIZATION PROPERTIES OF ISONIAZID LOADED CHITOSAN MICROSPHERES
Kundawala, A. J., Patel, V. A., Patel, H. V., & Choudhary, D. (2018) · International Journal of Pharmaceutical Sciences and Drug Research · doi:10.25004/ijpsdr.2011.030405 · Cited by 16
Quinolones for mycobacterial infections
Rubinstein, E., & Keynan, Y. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.03.005 · Cited by 12
Pathogenesis of tuberculosis
Venkataraman, M. (1992) · Immunology Today · doi:10.1016/0167-5699(92)90142-t · Cited by 10
PREPARATION OF ISONIAZID AS DRY POWDER FORMULATIONS FOR INHALATION BY PHYSICAL MIXING AND SPRAY DRYING
Sawatdee, S., Worakul, N., & Srichana, T. (2006) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 9

Research works printed but not linked: 2

Kundawala, 2012, Treating tuberculosis with chitosan microparticles loaded with rifampicin as respirable powder for pulmonary delivery Indian, J. Novel Drug Deliv., 4, 57
Garcia-Contreras, 2007, Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model, Antimicrob. Agents Chemother., 51, 2830, 10.1128/AAC.01164-06 · DOI

Sorted by citations

Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles
Singh, A. P., Biswas, A., Shukla, A., & Maiti, P. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0068-3 · Cited by 645
Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems
Baryakova, T. H., Pogostin, B. H., Langer, R., & McHugh, K. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00670-0 · Cited by 566
The Multirole of Liposomes in Therapy and Prevention of Infectious Diseases
Nisini, R., Poerio, N., Mariotti, S., Santis, F. D., & Fraziano, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00155 · Cited by 308
A roadmap to pulmonary delivery strategies for the treatment of infectious lung diseases
He, S., Gui, J., Xiong, K., Chen, M., Gao, H., & Fu, Y. S. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01307-x · Cited by 188
Soy Lecithin-Derived Liposomal Delivery Systems: Surface Modification and Current Applications
Le, N. T. T., Cao, V. D., Nguyen, T. N. Q., Le, T. T. H., Tran, T. T., & Thi, T. T. H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194706 · Cited by 180

See all 185

Authors: Pham, D.-D., Fattal, E., & Tsapis, N.
Affiliations: Centre National de la Recherche Scientifique (FR)
Corresponding author: Pham, Dinh-Duy
Tsapis, Nicolas
ORCID: Fattal, Elias
Tsapis, Nicolas
Venue: International Journal of Pharmaceutics
Publisher: Elsevier BV
Published: 2015-01
Volume: 478
Issue: 2
Pages: 517-529
ISSN: 0378-5173 (ISSN-L)
DOI: 10.1016/j.ijpharm.2014.12.009
OpenAlex: W2076894650
Cited by: 185
References: 121
Citations by year: 2026: 5 · 2025: 11 · 2024: 11 · 2023: 23 · 2022: 15 · 2021: 12 · 2020: 26 · 2019: 25 · 2018: 16 · 2017: 14 · 2016: 18 · 2015: 9
FWCI: 2.34
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: International Journal of Pharmaceutics (publishedVersion)
PubMed (publishedVersion)
Funders: ANR (ANR-10-LABX-33)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
Keywords: pulmonary drug delivery, tuberculosis, antitubercular agents, dry powder inhaler, liposomes, microparticles, nanoparticles, alveolar macrophages, multidrug-resistant tuberculosis, medication adherence, controlled drug release, targeted drug delivery
MeSH terms: Administration, Inhalation, Animals, Antitubercular Agents, Humans, Powders, Tuberculosis, Pulmonary, Drug Delivery Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Pulmonary drug delivery systems for tuberculosis treatment

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks